ESOC 2024 | Updates from ESOC 2024: TRACE III, SWITCH, and TRUTH

Adnan Mujanovic, MD, PhD Candidate, Inselspital, Bern University Hospital, Bern, Switzerland, shares his highlights from ESOC 2024. He mentions several tenecteplase trials which were presented this year, including the TRACE III trial which showed improved functional outcomes in patients with large vessel occlusion treated with tenecteplase compared to standard medical treatment. A large systematic review and meta-analysis of nine trials was also presented that showed better outcomes with tenecteplase versus alteplase. Dr Mujanovic also highlights the SWITCH trial of decompressive craniectomy for severe deep intracerebral hemorrage, which provided marginal evidence that surgery plus optimal medical treatment might be superior to optimal medical treatment alone. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.